Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2021

View Archived Issues

FDA approves IND for JAR-914 in Duchenne muscular dystrophy

Remdesivir data in pediatric patients with COVID-19

MGTA-145 plus plerixafor effectively mobilizes stem cells for transplant in phase I study

Phase II trial underway in Mali for CIS-43LS to prevent P. falciparum infection

Izcargo approved in Japan for the treatment of MPS II

U.S. researchers patent GTPase KRAS mutant inhibitors

Ofatumumab approved in Japan for multiple sclerosis

Janssen's Darzquro approved for multiple myeloma in Japan

Breyanzi CAR-T therapy receives lymphoma approvals in Japan

ChemWerth presents new JAK1 inhibitors

Bristol Myers Squibb divulges DGKA and/or DGKZ inhibitors

Idorsia Pharmaceuticals synthesizes LGALS inhibitors

Biotest presents FVIII-based recombinant proteins for hemophilia A

First trial evaluating KCNQ2/3 positive modulator ezogabine in depression and anhedonia

Japanese approval of Lenvima for unresectable thymic carcinoma

Japanese MHLW approves Remitoro for relapsed or refractory PTCL and CTCL

Basilea reports further interim data from phase II study of derazantinib in bile duct cancer

LINC-4 phase III data presented for osilodrostat in patients with Cushing's disease

GAUSS identifies subsets, improves UK Biobank interpretation

Kinase links innate immunity to MDS

Phase II data for xanomeline/trospium as therapy for patients with schizophrenia

Clover initiates phase II/III study of adjuvanted S-Trimer COVID-19 vaccine candidate

LIBERTY randomized withdrawal study of relugolix combination therapy meets primary endpoint

ProQR plans phase II/III studies with QR-421a in Usher syndrome based on phase I/II trial analysis

FDA clears IND for phase I/II trial of EO-2463 for indolent NHL

CVnCoV protects against SARS-CoV-2 B.1.351 variant in preclinical challenge study

Ostabaro approved in Japan for osteoporosis in patients at high risk of fractures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...